Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: John Dwyer who wrote (334)	4/20/1998 12:16:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 1494

John, I found the listing requirements: nasdaq.com Assuming the price stays above $1, NTII would have qualified for continuing listing, but doesn't qualify for a new listing, which is what I assume they would now have to do. If they did a reverse split to get the price above $5, then they'd need to meet the $4m in net tangible assets tests, which is probably close to where they are now. So maybe they could re-list if they did a reverse split. Peter

To: John Dwyer who wrote (334)	5/7/1998 8:27:00 AM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

NTII's memantine is in Phase II trials for AIDS related dementia. The attached article suggest how severe a problem it is and how difficult it is to treat. Memantine is a neuroprotectant. Although it won't eliminate the AIDS virus. it will protect the neural tissue from damage by the virus. Results should be out by the end of the year. This should constitute a fairly large market for memantine as it would have to be taken daily as long as the virus was present in the patient. As of now, tragically, that means for the rest of his/her life. John de C 11:27 AM ET 05/06/98 Drug seen ineffective against AIDS-linked brain virus BOSTON (Reuters) - Tests show that the anti-cancer drug cytarabine is not effective for treating AIDS patients suffering from a deadly brain infection, according to a report in Thursday's New England Journal of Medicine. Cytarabine, sold under the brand name Cytosar-U by Pharmacia & UpJohn, is frequently prescribed for people with progressive multifocal leukoencephalopathy (PML). The once-rare condition makes brain cells deteriorate, causes vision problems, confusion and muscle weakness. The condition strikes about 4 percent of patients with AIDS, typically killing them in about three months. There is no other effective therapy. To test cytarabine, Colin D. Hall of the University of North Carolina and his colleagues gave either a placebo or the drug to 57 volunteers with PML for 24 weeks. All received anti-virus drugs as well. The cytarabine did not improve the survival rate, which averaged less than four months for people taking the medicine. Twenty-two of the 57 patients died before they could be given the full treatment with the medicine. REUTERS